Negin Sadi Khosroshahi, Sama Akbarzadeh, Elaheh Malek Abbaslou, Ali Rajabi, Adel Abdi, Ali Saber, Amir Reza Pakmanesh, Reza Safaralizadeh
{"title":"Upregulation of lncRNA ANRASSF1 is associated with the lymph node metastasis and <i>H. pylori</i> infection in gastric cancer.","authors":"Negin Sadi Khosroshahi, Sama Akbarzadeh, Elaheh Malek Abbaslou, Ali Rajabi, Adel Abdi, Ali Saber, Amir Reza Pakmanesh, Reza Safaralizadeh","doi":"10.1080/17520363.2025.2529769","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer is the fifth most common malignancy worldwide. Early diagnosis of GC can increase survival rate and treatment outcome. In the present study, the expression of lncRNA ANRASSF1 was evaluated in gastric tumor tissues.</p><p><strong>Methods: </strong>One hundred and two pairs of gastric tumors and non-tumor tissues were collected from Tabriz International Valiasr Hospital, Iran. RNA was extracted, followed by cDNA synthesis. Expression of ANRASSF1 was assessed using real-time PCR method.</p><p><strong>Results: </strong>ANRASSF1 was significantly overexpressed in GC (<i>p</i> < 0.001). We found a significant association between ANRASSF1 expression and lymph node metastasis (<i>p</i> = 0.014), <i>Helicobacter pylori</i> infection (<i>p</i> = 0.029), and Lauren subtypes (<i>p</i> = 0.0001).</p><p><strong>Conclusion: </strong>LncRNA ANRASSF1 appears to have an oncogenic role in GC, and it may be regarded as a diagnosis and prognostic biomarker in patients with GC.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"571-576"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2529769","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Gastric cancer is the fifth most common malignancy worldwide. Early diagnosis of GC can increase survival rate and treatment outcome. In the present study, the expression of lncRNA ANRASSF1 was evaluated in gastric tumor tissues.
Methods: One hundred and two pairs of gastric tumors and non-tumor tissues were collected from Tabriz International Valiasr Hospital, Iran. RNA was extracted, followed by cDNA synthesis. Expression of ANRASSF1 was assessed using real-time PCR method.
Results: ANRASSF1 was significantly overexpressed in GC (p < 0.001). We found a significant association between ANRASSF1 expression and lymph node metastasis (p = 0.014), Helicobacter pylori infection (p = 0.029), and Lauren subtypes (p = 0.0001).
Conclusion: LncRNA ANRASSF1 appears to have an oncogenic role in GC, and it may be regarded as a diagnosis and prognostic biomarker in patients with GC.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
